Browsing by Author "Yildiz, F."
Now showing 1 - 15 of 15
- Results Per Page
- Sort Options
Item Adjuvant Radiotherapy in Cervical Cancer Patients: TROD Gynecologic Group Study(2020) Gultekin, M.; Esen, C. S. Beduk; Balci, B.; Alanyali, S.; Yildirim, B. Akkus; Ergen, S. A.; Sahinler, I.; Cetin, I. Alsan; Onal, C.; Yildiz, F.; Ozsaran, Z.; 0000-0002-2742-9021; D-5195-2014Item Adjuvant Radiotherapy in Clear Cell and Serous Papillary Endometrial Cancer(2015) Sari, S. Yuce; Gultekin, M.; Yuce, K.; Ayhan, A.; Altundag, O.; Kars, A.; Turker, A.; Ocalan, R.; Hurmuz, P.; Yildiz, F.; 0000-0003-0197-6622; W-9219-2019; ABX-1273-2022; AAJ-5802-2021Item Adjuvant Small Pelvic Radiation Therapy in Cervical Cancer Patients With Minor Risk Factors(2016) Sari, S. Yuce; Guler, O. C.; Gultekin, M.; Onal, C.; Yildiz, F.; 0000-0001-6908-3412; ABX-1273-2022; AAC-5654-2020; HOC-5611-2023Item The Clinical Outcomes Of Breast Cancer Lung Metastasis Treated With Stereotactic Body Radiotherapy(2022) Guler, O. C.; Sari, S. Yuce; Gultekin, M.; Yildiz, F.; Onal, C.Item Disease Characteristics of Psoriatic Arthritis Patients May Differ According to Age at Psoriasis Onset: Cross-Sectional Data from the Psoriatic Arthritis-International Database(2021) Bilgin, E.; Aydin, S. Z.; Tinazzi, I.; Bayindir, O.; Kimyon, G.; Ozisler, C.; Dogru, A.; Dalkilic, E.; Aksu, K.; Cetin, G. Yildirim; Yilmaz, S.; Solmaz, D.; Omma, A.; Can, M.; Kucuksahin, O.; Yavuz, S.; Ersozlu, E.D.; Kilic, L.; Tarhan, E.F.; Tufan, M.A.; Akyol, L.; Cinar, M.; Erden, A.; Gonullu, E.; Yildiz, F.; Bakirci, S.; Erbasan, F.; Esmen, S.Ergulu; Kucuk, A.; Tufan, A.; Balkarali, A.; Mercan, R.; Erten, S.; Akar, S.; Kasifoglu, T.; Duruoz, T.; Yazisiz, V.; Kalyoncu, U.; 32662407Objective To explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort. Methods The data from a multicentre psoriatic arthritis database was analysed. Patients were grouped according to age at psoriasis onset (early onset; 40 years of age, late-onset; 40 years of age) and disease characteristics of the groups were compared by adjusting for BMI and PsA duration, where necessary. Results At the time of analyses, 1634 patients were recruited [62.8% females; early onset 1108 (67.8%); late-onset, 526 (32.2%)]. The late-onset group was more over-weight [66.8% vs. 86.8%, p<0.001; adjusted for age -aOR 1.55 (1.11-2.20; 95% CI)]. The early onset group had more scalp psoriasis at onset (56.7% vs. 43.0%, p<0.001), whereas extremity lesions were more common in the late-onset group (63.8% vs. 74.2%, p<0.001). Axial disease in males and psoriatic disease family history in females were significantly higher in the early onset group [38.0% vs. 25.4%; p=0.005; adjusted for PsA duration -aOR 1.76 (1.19-2.62; 95% CI) / 39.5% vs. 30.1%; p=0.003; OR 1.51 (1.15-1.99; 95% CI), respectively]. Psoriatic disease activity parameters, patient-physician reported outcomes and HAQ-DI scores were similar in both groups. Conclusion Clinical features of PsA may be affected by the age at onset of PsO. Different genetic backgrounds in early and late-onset PsO may be driving the differences in psoriasis and PsA phenotypes.Item Economic Burden of Severe Asthma in Turkey: A Cost of Illness Study from Payer Perspective(2021) Bavbek, S.; Malhan, S.; Mungan, D.; Misirligil, Z.; Erdinc, M.; Gemicioglu, B.; Oguzulgen, I. Kivilcim; Oksuz, E.; Yildiz, F.; Yorgancioglu, A.; 0000-0002-5723-5965; 32372589; K-8238-2012Objective. To estimate economic burden of severe asthma in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods. This cost of illness study was based on identification of per patient annual direct medical costs for the management of severe asthma in Take, from payer perspective. Average per patient direct medical cost was calculated based on cost items related to outpatient visits laboratory and radiological tests, hospitalizations and interventions drug treatment and equipment, and co-morbidities/complications. Results. Based on total annual per patient costs calculated for outpatient admission ($177.91), laboratory and radiological tests ($ 8232), hospitalization/interventions ($1,154.55), drug treatment/equipment ($2,289.63) and co-morbidities ($ 661.39) cost items, total per patient annual direct medical cost related to management of severe asthma was calculated to be $ 4,369.76 from payer perspective. Drug treatment/equipment (524%) was the main cost driver in the management of severe asthma in Turkey, as followed by hospitalizations/interventions (264%) and co-morbidities (15.2%). Conclusions. In conclusion, our findings indicate that managing patients with severe asthma pose a considerable burden to health economics in Turkey with medications as the main cost driver.Item The impact of lymph node ratio in patients with stage IIIC endometrial carcinoma(2021) Onal, C.; Sari, S. Yuce; Yavas, G.; Guler, O. C.; Yigit, E.; Oymak, E.; Gultekin, M.; Yildiz, F.Item Patterns of Recurrence and Survival Rates in Endometrial Cancer According to ESMO-ESGO-ESTRO Risk Classification(2018) Sari, S. Yuce; Gultekin, M.; Rahatli, S.; Altundag, O.; Turker, A.; Kars, A.; Yuce, K.; Ayhan, A.; Ozyigit, G.; Yildiz, F.; 0000-0003-3163-7429; 0000-0003-0197-6622; AAJ-3047-2021; W-9219-2019Item Radiation Therapy Outcomes After Skin-Sparing Mastectomy and Implant-Based Breast Reconstruction(2016) Sari, S. Yuce; Kotek, A.; Gultekin, M.; Yildirim, B. Akkus; Onal, C.; Ozyigit, G.; Gurkaynak, M.; Yildiz, F.; https://orcid.org/0000-0001-6661-4185; V-5717-2017; HOC-5611-2023Item Stage Ib Endometrial Cancer: The Role of Number of Dissected Lymph Nodes(2015) Sari, S. Yuce; Gultekin, M.; Yazici, G.; Tulunay, G.; Boran, N.; Dursun, P.; Gungor, T.; Yuce, K.; Ortac, F.; Ayhan, A.; Yildiz, F.Item Stage II Endometrial Cancer: External Pelvic Radiation Therapy Alone or External Pelvic Radiation Therapy With Brachytherapy(2015) Sari, S. Yuce; Gultekin, M.; Dursun, P.; Salman, C.; Ozgul, N.; Ortac, F.; Yuce, K.; Ayhan, A.; Yildiz, F.Item Treatment Outcomes of Breast Cancer Lung Metastasis Treated with Stereotactic Body Radiotherapy(2020) Guler, O. C.; Sari, S. Y.; Gultekin, M.; Yildirim, B. A.; Ozyilkan, O.; Yildiz, F.; Onal, C.; 0000-0001-6661-4185; V-5717-2017; ABX-1273-2022; HOC-5611-2023Item Treatment Outcomes of Definitive or Postoperative Radiotherapy in Elderly Cervical Cancer Patients(2015) Guler, O. C.; Sari, S. Y.; Birge, S. D.; Gultekin, M.; Yildiz, F.; Onal, C.; 0000-0002-4221-4459; 0000-0001-6908-3412; AAQ-5865-2020; AAC-5654-2020; HOC-5611-2023; ABX-1273-2022Item The Utility of Dissected Lymph Node Number and Lymph Node Metastasis Ratio In Stage IIIC Endometrium Adenocarcinoma: A Multicentric Analysis(2018) Yildirim, B. Akkus; Onal, C.; Sari, S. Yuce; Yavas, G.; Gultekin, M.; Guler, O. C.; Yildiz, F.; Akyurek, S.; https://orcid.org/0000-0001-6661-4185; V-5717-2017; HOC-5611-2023Item Validation of the ESMO-ESGO-ESTRO Consensus Conference Risk Grouping in Turkish Endometrial Cancer Patients Treated with Comprehensive Surgical Staging(2019) Gultekin, M.; Guler, O. C.; Sari, S. Yuce; Yildirim, B. Akkus; Mustafayev, T. Z.; Atalar, B.; Bolukbasi, Y.; Onal, H. C.; Celik, H.; Yuce, K.; Ayhan, A.; Yildiz, F.; 0000-0001-6908-3412; AAC-5654-2020